U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041060) titled 'Evaluation of the Efficacy and Safety of Eolo in Patients With NERD' on May 30.
Brief Summary: Background: Non-erosive reflux disease (NERD) is a prevalent subtype of gastroesophageal reflux disease (GERD), often inadequately managed with proton pump inhibitors (PPIs) alone. Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts, has been proposed as an adjunctive therapy to enhance symptom relief and mucosal protection.
Objective: This study evaluates the efficacy and safety of a nutraceutical [Eolo(R), Cristalfarma s.r.l. - Milan (IT)] in combination with PPIs or alone...